Welcome to our dedicated page for Cv Sciences news (Ticker: CVSI), a resource for investors and traders seeking the latest updates and insights on Cv Sciences stock.
CV Sciences, Inc. (CVSI) operates at the intersection of scientific innovation and natural wellness, developing hemp-derived supplements and plant-based nutrition solutions. This page serves as the definitive source for official company announcements, research breakthroughs, and operational developments.
Investors and industry stakeholders will find curated updates spanning regulatory milestones, product launches, and peer-reviewed studies validating CVSI's formulations. The archive includes earnings reports, manufacturing expansions, and clinical trial outcomes supporting their +PlusCBD and Cultured Foods brands.
All content undergoes rigorous verification to ensure alignment with financial disclosure standards and scientific accuracy. Users can efficiently track the company's progress in obtaining self-affirmed GRAS statuses, scaling global distribution networks, and advancing pet wellness innovations.
Bookmark this resource for real-time access to CV Sciences' advancements in cannabinoid research, nutraceutical safety protocols, and strategic partnerships within the consumer health sector. Regularly updated to reflect the company's evolving role in science-driven wellness solutions.
CV Sciences (OTCQB:CVSI) reported its fiscal year 2024 results with revenue of $15.7 million, slightly down 1.9% from $16.0 million in 2023. The company's Q4 2024 revenue was $3.9 million, up 2.2% from $3.8 million in Q4 2023.
Key financial metrics include improved gross margin of 45.6% for 2024 (up from 44.3% in 2023), reduced operating expenses by 5.4% to $9.4 million, and an adjusted EBITDA loss of $0.8 million, significantly improved from a $2.3 million loss in 2023.
Notable developments include the acquisition of Elevated Softgels, launch of +PlusHLTH™ supplement line, partnership with Chewy for pet products, and introduction of Lunar Fox vegan food line. The company maintained its position as the top-selling hemp extract brand in natural product retail.
CV Sciences (OTCQB:CVSI) has launched Lunar Fox Food Co., a new line of plant-based food products targeting the growing vegan market. The product line includes seven innovative offerings: CHEDDRLY MAC! (vegan mac and cheese), CHEDDRLY! (dairy-free cheese substitute), WHISKED! (egg substitute for omelets), BAKED! (dairy-free egg alternative for baking), MANGIA! (Italian-seasoned meatless alternative), FIESTA! (Mexican-spiced meatless alternative), and BOLOGNESE! (plant-based Italian sauce).
All products are 100% natural, gluten-free, and available at select retailers and through lunarfoxfoods.com. This launch expands CV Sciences' portfolio, which includes +PlusHLTH cannabinoid-free supplements, +PlusCBD Extra Support Gummies, Reserve gummies, and pet products.
CV Sciences (OTCQB:CVSI), a consumer wellness company focused on hemp extracts and natural ingredients, has scheduled its Year End and Fourth Quarter 2024 financial results announcement for March 27, 2025, before market opening.
The company will host a conference call with investors at 7:00 a.m. Pacific Time (10:00 a.m. Eastern Time) on the same day. Investors can participate through a webcast available on the company's Investor Relations website or by dialing (877) 407-0784 for U.S. callers or (201) 689-8560 for international participants.
A replay of the call will be accessible until April 3, 2025, by dialing (844) 512-2921 (U.S.) or (412) 317-6671 (international) with confirmation code 13752212.
CV Sciences (OTCQB:CVSI) has launched new 2.5 mg THC Fizz Tablets as part of their Aura Collection product line. The lemon-flavored, fast-acting tablets are designed to be dissolved in beverages, offering an alcohol-free alternative for relaxation and stress relief. The vegan and gluten-free tablets are made with premium hemp extract and are now available at select retailers and the company's website.
This launch follows the September 2024 introduction of the Aura Collection, which includes Serene and Illuminate Gummies combining THC and CBD. The expansion adds to CV Sciences' growing portfolio, which recently added +PlusHLTH™ cannabinoid-free supplements, +PlusCBD™ Reserve gummies, and +PlusCBD™ pet products.
CV Sciences (OTCQB:CVSI) has entered into a definitive agreement to acquire Extract Labs, a premium cannabinoid products manufacturer. The acquisition, valued at $400,000 in cash and $1,000,000 in CVSI shares at closing, includes potential additional share-based earnouts up to $600,000 based on revenue targets. Extract Labs, a GMP-certified and FDA-registered facility, offers manufacturing flexibility and efficient product development capabilities. The deal aims to increase sales, optimize operations, and enable in-house production of select +PlusCBD™ products. The transaction is expected to close in Q1 2025.
CV Sciences reported Q3 2024 financial results with revenue of $3.9 million, down 5% from Q3 2023's $4.1 million. Gross margin improved to 46.0% compared to 45.1% in Q3 2023. The company maintained a cash balance of $1.0 million and secured financing of $0.9 million from Streeterville. Notable developments include the launch of +PlusHLTH™, a cannabinoid-free supplement line, and expansion of pet product offerings. B2B sales declined 9% due to state CBD regulations. The company reported an operating loss of $0.3 million and negative adjusted EBITDA of $75,000, showing improvement from Q3 2023.
CV Sciences (OTCQB:CVSI), a consumer wellness company focused on hemp extracts and natural ingredients, has announced it will release its Q3 2024 financial results on November 14, 2024, before market open. The company will host a conference call with investors at 7:00 a.m. Pacific Time (10:00 a.m. Eastern Time) on the same day. The webcast will be available on the company's Investor Relations website and archived for approximately 30 days. U.S. investors can join via (877) 407-0784, while international callers can use (201) 689-8560. A replay will be available until November 21, 2024.
CV Sciences (OTCQB: CVSI) has launched +PlusHLTH, a new line of cannabinoid-free supplements designed to enhance focus, mood, energy, and metabolism. The product line includes three variations:
1. Clarity: A cognitive enhancer with DMAE, Huperzine A, Rhodiola, and Lion's Mane.
2. Peace: A stress-relief formula with Holy Basil, Lemon Balm, St. John's Wort, and L-Theanine.
3. ReShape: A metabolism and weight management supplement with Berberine, OEA, and Cinnamon.
The new products are available nationwide at select retailers and on the company's website. CEO Joseph Dowling stated that +PlusHLTH fills a growing demand for natural supplements addressing key wellness challenges, offering a cannabinoid-free alternative or complement to their CBD-based product line.
CV Sciences, Inc. (OTCQB:CVSI) reported its Q2 2024 financial results, showing stable revenue of $4.0 million, consistent with Q2 2023 and Q1 2024. The company achieved a gross margin of 47.0%, its best in 13 quarters, up from 43.3% in Q2 2023. CV Sciences maintained its position as the top-selling hemp extract brand in natural product retail sales. The company acquired Elevated Softgels and appointed Maxim Group as a financial advisor. Despite an operating loss of $0.6 million, this was an improvement from the $1.1 million loss in Q2 2023. CV Sciences reported negative adjusted EBITDA of $6,000, close to break-even, compared to $0.9 million in Q2 2023. The company's cash balance stood at $0.5 million at quarter-end, down from $1.3 million at the end of 2023.
CV Sciences (OTCQB: CVSI), a leading consumer wellness company specializing in hemp extracts and natural products, has announced its plans to release financial results for the second quarter of 2024 on Tuesday, August 13, 2024, before the stock market opens. The company will host a conference call with investors at 7:00 a.m. Pacific Time on the same day.
Investors can access the webcast through the company's Investor Relations website or directly via a provided link. For those preferring to participate by phone, U.S. callers can dial (877) 407-0784, while international callers should use (201) 689-8560. A replay of the call will be available until August 20, 2024.